Tuberculosis in Hematopoietic Stem Cell Transplant Recipients
Literature on tuberculosis (TB) occurring in recipients of Hematopoietic Stem Cell Transplant (HSCT) is scanty even in countries where TB is common. Most reports of TB in HSCT patients were from ASIA, in fact the TB incidence ranging from 0.0014 (USA) to 16% (Pakistan). There are few reports of TB d...
Main Authors: | , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Università Cattolica del Sacro Cuore
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867227/ |
id |
pubmed-3867227 |
---|---|
recordtype |
oai_dc |
spelling |
pubmed-38672272013-12-20 Tuberculosis in Hematopoietic Stem Cell Transplant Recipients Ramos, Jéssica Fernandes Batista, Marjorie Vieira Costa, Silvia Figueiredo Review Article Literature on tuberculosis (TB) occurring in recipients of Hematopoietic Stem Cell Transplant (HSCT) is scanty even in countries where TB is common. Most reports of TB in HSCT patients were from ASIA, in fact the TB incidence ranging from 0.0014 (USA) to 16% (Pakistan). There are few reports of TB diagnosis during the first two weeks after HSCT; most of cases described in the literature occurred after 90 days of HSCT, and the lung was the organ most involved. The mortality ranged from 0 to 50% and is higher in allogeneic HSCT than in autologous. There is no consensus regarding the screening with tuberculin skin test or QuantiFERON-TB gold, primary prophylaxis for latent TB, and whether the epidemiologic query should be emphasized in developing countries with high prevalence of TB. Università Cattolica del Sacro Cuore 2013-11-04 /pmc/articles/PMC3867227/ /pubmed/24363876 http://dx.doi.org/10.4084/MJHID.2013.061 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
repository_type |
Open Access Journal |
institution_category |
Foreign Institution |
institution |
US National Center for Biotechnology Information |
building |
NCBI PubMed |
collection |
Online Access |
language |
English |
format |
Online |
author |
Ramos, Jéssica Fernandes Batista, Marjorie Vieira Costa, Silvia Figueiredo |
spellingShingle |
Ramos, Jéssica Fernandes Batista, Marjorie Vieira Costa, Silvia Figueiredo Tuberculosis in Hematopoietic Stem Cell Transplant Recipients |
author_facet |
Ramos, Jéssica Fernandes Batista, Marjorie Vieira Costa, Silvia Figueiredo |
author_sort |
Ramos, Jéssica Fernandes |
title |
Tuberculosis in Hematopoietic Stem Cell Transplant Recipients |
title_short |
Tuberculosis in Hematopoietic Stem Cell Transplant Recipients |
title_full |
Tuberculosis in Hematopoietic Stem Cell Transplant Recipients |
title_fullStr |
Tuberculosis in Hematopoietic Stem Cell Transplant Recipients |
title_full_unstemmed |
Tuberculosis in Hematopoietic Stem Cell Transplant Recipients |
title_sort |
tuberculosis in hematopoietic stem cell transplant recipients |
description |
Literature on tuberculosis (TB) occurring in recipients of Hematopoietic Stem Cell Transplant (HSCT) is scanty even in countries where TB is common. Most reports of TB in HSCT patients were from ASIA, in fact the TB incidence ranging from 0.0014 (USA) to 16% (Pakistan). There are few reports of TB diagnosis during the first two weeks after HSCT; most of cases described in the literature occurred after 90 days of HSCT, and the lung was the organ most involved. The mortality ranged from 0 to 50% and is higher in allogeneic HSCT than in autologous. There is no consensus regarding the screening with tuberculin skin test or QuantiFERON-TB gold, primary prophylaxis for latent TB, and whether the epidemiologic query should be emphasized in developing countries with high prevalence of TB. |
publisher |
Università Cattolica del Sacro Cuore |
publishDate |
2013 |
url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867227/ |
_version_ |
1612039598071873536 |